Introduction:

Functional mitral regurgitation is defined as regurgitation of blood flow from the left ventricle to the left atrium during the systole ventricular, which produces at short term, a heart failure because of a geometric alteration, that leads to a poor functioning of the papillary muscles and chordae tendinae, due to blood flow compensation. Percutaneous treatment with Mitraclip (Abbott Vascular) has shown an improvement in mortality, morbidity and quality of life in patients with severe functional mitral regurgitation.

Objective:

To describe COAPT score in patients with functional mitral regurgitation after receiving management with the Mitraclip® device in a cardiovascular institution between July of 2016 and May 2024.

Methods:

An observational descriptive study was performed with the application of a risk index score.

Results:

59 patients met inclusion criteria for the study. The mean age was 71 ± 8.3 years old, 83% had arterial hypertension, 74.5% hypercholesterolemia, 57.6% coronary heart disease and 23% previous cardiac revascularization. There were 25 heart failure hospitalizations during two year-long (42.3% of the population), and 4 mortality events (6.77% 2-year-long period). Left ventricular ejection fraction (LVEF) less than 25% (OR: 7.38; 95%CI: 1.83-28.9), left ventricle end-systole diameter greater than 5.5 cm (OR: 3.56; 95%CI: 1.1-10.9) and left ventricular end-diastole diameter greater than 7.5 cm (OR: 25.3; 95%CI: 1.2-509) are predictors of hospitalization for heart failure, but not of mortality with significant results.

Conclusions:

The COAPT score in the study population did not show significant results for mortality, although left ventricular diameter measurements (both systolic and diastolic) as well as LVEF less than 25% are predictors for hospitalization for heart failure in two years of follow up.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )